Retraction Note: Evaluating polymicrobial immune responses in patients suffering from tick-borne diseases

Garg, Kunal; Meriläinen, Leena; Franz, Ole; Pirttinen, Heidi; Quevedo-Diaz, Marco; Croucher, Stephen M.; Gilbert, Leona

doi:10.1038/s41598-022-07207-2

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A series of serial dilutions of the antigens from (1/400 to 1/102400) 0.25, 0.124, 0.062, 0.031, 0.015, 0.007, 0.001, and 0.0009 µg were used to titrate S/N and analyze detection along with a positive (COP4, COP5, COP6) and negative sera (TEZ1). An ELISA was set up according to the previously described procedure [24]. Sera samples at 1/100 dilution were used to demonstrate titration of S and N antigens.…”

Section: Patient Specimensmentioning

confidence: 99%

“…Sera samples at 1/100 dilution were used to demonstrate titration of S and N antigens. Additionally, SARSPLEX was established according to ISO13485 protocols already established [24,25], except with the following additions: Human IgA (Sigma) was used as a positive control and Human IgG (Sigma) as a negative control for the secondary antibody anti-human IgA (Abcam).…”

Section: Patient Specimensmentioning

confidence: 99%

See 1 more Smart Citation

SARSPLEX: Multiplex Serological ELISA with a Holistic Approach

Garg¹,

Campolonghi²,

Schwarzbach

et al. 2022

Viruses

View full text Add to dashboard Cite

Currently, there are over 602 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases and 6.4 million COVID-19 disease-related deaths worldwide. With ambitious vaccine strategies, reliable and accurate serological testing is needed to monitor the dynamics of the novel coronavirus pandemic and community immunity. We set out to improve serological testing of the immune response against SARS-CoV-2. We hypothesize that by multiplexing the serological diagnostic test kit (SARSPLEX) and screening for three antibodies, an even more robust diagnostic can be developed. A total of 293 sera were analyzed for IgM, IgG, or IgA immune reactions to the subunit 1 spike glycoprotein and the nucleocapsid protein in a standardized ELISA platform. Testing IgM, IgG, and IgA demonstrated high positive and negative agreements compared to RT-PCR and serology reference tests. Comparison with the pre-2019-CoV (n = 102) samples highlighted the specificity of this test kit and indicated that no unspecific binding, even with the summer flu patients (n = 44), was detected. In addition, SARSPLEX demonstrated to be a valuable occupational surveillance tool used in a functional medicine facility. With increased and broader testing, SARSPLEX will be a valuable tool in monitoring immunity and aid in prioritizing access to the SARS-CoV-2 vaccine for high-risk patients.

show abstract

Section: Patient Specimensmentioning

confidence: 99%

Section: Patient Specimensmentioning

confidence: 99%

SARSPLEX: Multiplex Serological ELISA with a Holistic Approach

Garg¹,

Campolonghi²,

Schwarzbach

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…14,15 Multiple papers have documented B. henselae exposure in patients with Lyme disease and patients with co-infections may experience more severe and protracted clinical manifestations. [15][16][17][18] Currently, there is no single treatment effective for Bartonellaassociated diseases and antibiotic recommendations differ depending on specific presentations. 19 The first-line antibiotics for treatment of Bartonella-associated infections include doxycycline (DOX), erythromycin, azithromycin (AZI), gentamicin (GEN), rifampin (RIF), and ciprofloxacin, as well as drug combinations such as DOX plus GEN or DOX plus RIF.…”

Section: Introductionmentioning

confidence: 99%